Compare iShares Core MSCI EAFE ETF (IEFA) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI EAFE ETF vs Medpace Holdings Inc — how do they compare? iShares Core MSCI EAFE ETF trades at $96.48 (market cap $189.19B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: iShares Core MSCI EAFE ETF is far larger — about 11.2× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, iShares Core MSCI EAFE ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI EAFE ETF for 40 Days and Medpace Holdings Inc for 14 Days on average.
| IEFA | MEDP | |
|---|---|---|
Market Cap | $189.19B | $16.82B |
Volume | 8,441,787 | 223,093 |
Sector | Broad Market / Factor | Health |
52-Week High | $101.41 | $630.19 |
52-Week Low | $85.06 | $393.42 |
Typical Hold Time | 40 Days | 14 Days |
Enterprise Value | — | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEFA, the iShares Core MSCI EAFE ETF, trades at $96.37, up 0.18% on the day, while technical indicators signal a bearish trend with moving averages and oscillators in sell territory. The fund provides exposure to developed markets outside North America, holding $196 billion in assets. Recent news highlights its role in international diversification strategies and comparisons with competing ETFs like Schwab's SCHF and State Street's SPDW.
The outlook for IEFA is influenced by global market sentiment and interest rate uncertainty, offering diversification benefits but facing headwinds from geopolitical tensions. Key risks include concentration in developed economies and currency fluctuations. Analyst comparisons favor IEFA for its scale and dividend yield, though expense ratios and performance relative to peers remain considerations for investors.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
